Publikationen

TNF SIGNALING IN PERITONEAL MESOTHELIAL CELLS: PIVOTAL ROLE OF cFLIPL.
Lüdemann WM, Heide D, Kihm L, Zeier M, Scheurich P, Schwenger V, Ranzinger J.
Perit Dial Int. 2017 Jan 17. pii: pdi.2016.00138. doi: 10.3747/pdi.2016.00138. [Epub ahead of print]

Morbidity, mortality and quality of life in the ageing haemodialysis population: results from the ELDERLY study.
Seckinger J, Dschietzig W, Leimenstoll G, Rob PM, Kuhlmann MK, Pommer W, Fraass U, Ritz E, Schwenger V.
Clin Kidney J. 2016 Dec;9(6):839-848.

Clementine juice has the potential for drug interactions - In vitro comparison with grapefruit and mandarin juice.
Theile D, Hohmann N, Kiemel D, Gattuso G, Barreca D, Mikus G, Haefeli WE, Schwenger V, Weiss J.
Eur J Pharm Sci. 2017 Jan 15;97:247-256. doi: 10.1016/j.ejps.2016.11.021.

Tissue Expression of Aquaporin 2 Is Correlated to Urine Output and Allograft Function in Sensitized Kidney Transplant Patients.
Klein K, Rübenacker S, Schaefer SM, Kihm LP, Schwenger V, Macher-Goeppinger S, Schemmer P, Süsald C, Zeier M, Morath C, Becker LE.
Transplant Proc. 2016 Oct;48(8):2629-2636. doi: 10.1016/j.transproceed.2016.06.056.

Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice.
Kälble F, Damaske J, Heide D, Arnold I, Richter F, Maier O, Eisel U, Scheurich P, Pfizenmaier K, Zeier M, Schwenger V, Ranzinger J.
PLoS One. 2016 Oct 18;11(10):e0163314. doi: 10.1371/journal.pone.0163314.

Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H, Nelges C, Täger T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JG, Clark AL, Frankenstein L.
Am Heart J. 2016 Aug;178:28-36. doi: 10.1016/j.ahj.2016.03.024.

Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients - Independently of Cardiac Failure.
Jotterand Drepper V, Kihm LP, Kälble F, Diekmann C, Seckinger J, Sommerer C, Zeier M, Schwenger V.
PLoS One. 2016 Jul 14;11(7):e0158741. doi: 10.1371/journal.pone.0158741.

Quantitative Histomorphometry of the Healthy Peritoneum.
Schaefer B, Bartosova M, Macher-Goeppinger S, Ujszaszi A, Wallwiener M, Nyarangi-Dix J, Sallay P, Burkhardt D, Querfeld U, Pfeifle V, Lahrmann B, Schwenger V, Wühl E, Holland-Cunz S, Schaefer F, Schmitt CP.
Sci Rep. 2016 Feb 19;6:21344. doi: 10.1038/srep21344.

Novel Endothelial Cell-Specific AQP1 Knockout Mice Confirm the Crucial Role of Endothelial AQP1 in Ultrafiltration during Peritoneal Dialysis.
Zhang W, Freichel M, van der Hoeven F, Nawroth PP, Katus H, Kälble F, Zitron E, Schwenger V.
PLoS One. 2016 Jan 13;11(1):e0145513

Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage.
Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A.
Arthritis Res Ther. 2015 Nov 21;17(1):337.

When is contrast-enhanced sonography preferable over conventional ultrasound combined with Doppler imaging in renal transplantation?
Zeisbrich M, Kihm LP, Drüschler F, Zeier M, Schwenger V.
Clin Kidney J. 2015 Oct;8(5):606-14.

Low-Sodium Versus Standard-Sodium Peritoneal Dialysis Solution in Hypertensive Patients: A Randomized Controlled Trial.
Rutkowski B, Tam P, van der Sande FM, Vychytil A, Schwenger V, Himmele R, Gauly A; Low Sodium Balance Study Group.
Am J Kidney Dis. 2015 Sep 18. pii: S0272-6386(15)01125-7.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.
Circulation. 2015 Jul 7;132(1):27-39.

Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
Becker LE, Siebert D, Süsal C, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C.
Transplantation. 2015 Nov;99(11):2364-71.

Tailoring of alerts substantially reduces the alert burden in computerized clinical decision support for drugs that should be avoided in patients with renal disease.
Czock D, Konias M, Seidling HM, Kaltschmidt J, Schwenger V, Zeier M, Haefeli WE.
J Am Med Inform Assoc. 2015 Jul;22(4):881-7.

Peritoneal ultrafiltration in end-stage chronic heart failure.
Fröhlich H, Katus HA, Täger T, Lossnitzer N, Grossekettler L, Kihm L, Zeier M, Remppis A, Frankenstein L, Schwenger V.
Clin Kidney J. 2015 Apr;8(2):219-25.

Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid.
Müller-Krebs S, Nissle K, Tsobaneli J, Zeier M, Kihm LP, Kender Z, Fleming T, Nawroth PP, Reiser J, Schwenger V.
Front Med (Lausanne). 2015 Mar 10;2:10

High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.
Schaier M, Scholl C, Scharpf D, Schmitt WH, Schwenger V, Zeier M, Sommerer C.
Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i138-45

Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy.
Madhusudhan T, Wang H, Dong W, Ghosh S, Bock F, Thangapandi VR, Ranjan S, Wolter J, Kohli S, Shahzad K, Heidel F, Krueger M, Schwenger V, Moeller MJ, Kalinski T, Reiser J, Chavakis T, Isermann B.
Nat Commun. 2015 Mar 10;6:6496.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.
Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9.

Psychosocial and physical outcome following kidney donation-a retrospective analysis.
Sommerer C, Feuerstein D, Dikow R, Rauch G, Hartmann M, Schaier M, Morath C, Schwenger V, Schemmer P, Zeier M.
Transpl Int. 2015 Apr;28(4):416-28.

Contrast-enhanced ultrasonography in the early period after kidney transplantation predicts long-term allograft function.
Schwenger V, Hankel V, Seckinger J, Macher-Göppinger S, Morath C, Zeisbrich M, Zeier M, Kihm LP.
Transplant Proc. 2014 Dec;46(10):3352-7.

The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C, Schaier M, Morath C, Schwenger V, Rauch G, Giese T, Zeier M.
Trials. 2014 Dec 13;15:489.

Increased peritoneal damage in glyoxalase 1 knock-down mice treated with peritoneal dialysis.
Kihm LP, Müller-Krebs S, Holoch S, Schmuck S, Becker LE, Brownlee M, Zeier M, Fleming TH, Nawroth PP, Schwenger V.
Nephrol Dial Transplant. 2015 Mar;30(3):401-9.

Membrane nanotubes between peritoneal mesothelial cells: functional connectivity and crucial participation during inflammatory reactions.
Ranzinger J, Rustom A, Schwenger V.
Front Physiol. 2014 Oct 24;5:412.

daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans.
Mendler M, Schlotterer A, Ibrahim Y, Kukudov G, Fleming T, Bierhaus A, Riedinger C, Schwenger V, Herzig S, Hecker M, Tyedmers J, Nawroth PP, Morcos M.
Diabetologia. 2015 Feb;58(2):393-401.

Extracorporeal life support and plasmapheresis in a case of severe polyintoxication.
Koschny R, Lutz M, Seckinger J, Schwenger V, Stremmel W, Eisenbach C.
J Emerg Med. 2014 Nov;47(5):527-31.

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.
Shahzad K, Bock F, Dong W, Wang H, Kopf S, Kohli S, Al-Dabet MM, Ranjan S, Wolter J, Wacker C, Biemann R, Stoyanov S, Reymann K, Söderkvist P, Groß O, Schwenger V, Pahernik S, Nawroth PP, Gröne HJ, Madhusudhan T, Isermann B.
Kidney Int. 2015 Jan;87(1):74-84.

Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus.
Gao N, Dresel J, Eckstein V, Gellert R, Störch H, Venigalla RK, Schwenger V, Max R, Blank N, Lorenz HM, Tretter T.
Arthritis Rheumatol. 2014 Oct;66(10):2849-61.

The receptor for advanced glycation end-products (RAGE) plays a key role in the formation of nanotubes (NTs) between peritoneal mesothelial cells and in murine kidneys.
Ranzinger J, Rustom A, Heide D, Morath C, Schemmer P, Nawroth PP, Zeier M, Schwenger V.
Cell Tissue Res. 2014 Sep;357(3):667-79.

[Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group "heart-kidney" of the German Cardiac Society and the German Society of Nephrology].
Schwenger V, Remppis BA, Westenfeld R, Weinreich T, Brunkhorst R, Schieren G, Krumme B, Haller H, Schmieder R, Schlieper G, Frye B, Hoppe UC, Hoyer J, Keller T, Blumenstein M, Schunkert H, Mahfoud F, Rump LC.
Dtsch Med Wochenschr. 2014 Feb;139(7):e1-8.

Cellular effects of everolimus and sirolimus on podocytes.
Müller-Krebs S, Weber L, Tsobaneli J, Kihm LP, Reiser J, Zeier M, Schwenger V.
PLoS One. 2013 Nov 15;8(11):e80340.

Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.
Pelegrin L, Jakob E, Schmidt-Bacher A, Schwenger V, Becker M, Max R, Lorenz HM, Mackensen F.
J Rheumatol. 2014 Jan;41(1):84-90.

Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.
Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E.
Clin Res Cardiol. 2014 Feb;103(2):117-24.

Potential role of nanotubes in context of clinical treatments?
Ranzinger J, Rustom A, Schwenger V.
Commun Integr Biol. 2013 Jan 1;6(1):e22686.

[Cardiorenal syndrome: limits of heart failure therapy].
Großekettler L, Schmack B, Schwenger V.
Herz. 2013 Sep;38(6):569-77.

Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J.
Am J Ther. 2013 Mar-Apr;20(2):226-9.

Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K, Süsal C, Schäfer SM, Becker LE, Beimler J, Schwenger V, Zeier M, Schemmer P, Macher-Goeppinger S, Scherer S, Opelz G, Morath C.
Atheroscler Suppl. 2013 Jan;14(1):199-202.

Authors' response.
Schwenger V, Weigand M, Morath C.
Crit Care. 2013;17(1):407.

Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, Pelicci PG, Kashif M, Ranjan S, Schmidt S, Ritzel R, Schwenger V, Reymann KG, Esmon CT, Madhusudhan T, Nawroth PP, Isermann B.
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):648-53.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.
N Engl J Med. 2012 Dec 27;367(26):2482-94.

The influence of haemodialysis on haemodynamic measurements using transpulmonary thermodilution in patients with septic shock: an observational study.
Pathil A, Stremmel W, Schwenger V, Eisenbach C.
Eur J Anaesthesiol. 2013 Jan;30(1):16-20.

Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts.
Schwenger V, Weigand MA, Hoffmann O, Dikow R, Kihm LP, Seckinger J, Miftari N, Schaier M, Hofer S, Haar C, Nawroth PP, Zeier M, Martin E, Morath C.
Crit Care. 2012 Jul 27;16(4):R140.

[Renal replacement therapy for refractory heart failure].
Schwenger V, Remppis AB.
Internist (Berl). 2012 Jul;53(7):823-32.37.

Human RAGE antibody protects against AGE-mediated podocyte dysfunction.
Müller-Krebs S, Kihm LP, Madhusudhan T, Isermann B, Reiser J, Zeier M, Schwenger V.
Nephrol Dial Transplant. 2012 Aug;27(8):3129-36.

Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography.
Kihm LP, Blume C, Seckinger J, Hankel V, Stoffler D, Morath C, Zeier M, Schwenger V.
Transplantation. 2012 Jun 15;93(11):1125-9.

Glucose effects on the peritoneum: what can we learn from rodent models?
Müller-Krebs S, Zhang W, Kihm LP, Reiser J, Nawroth PP, Schwenger V.
Exp Clin Endocrinol Diabetes. 2012 Apr;120(4):197-8.

ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption.
Morath C, Becker LE, Leo A, Beimler J, Klein K, Seckinger J, Kihm LP, Schemmer P, Macher-Goeppinger S, Wahrmann M, Böhmig GA, Opelz G, Süsal C, Zeier M, Schwenger V.
Transplantation. 2012 Apr 27;93(8):827-34.

Buffer-dependent regulation of aquaporin-1 expression and function in human peritoneal mesothelial cells.
Zhai Y, Bloch J, Hömme M, Schaefer J, Hackert T, Philippin B, Schwenger V, Schaefer F, Schmitt CP.
Pediatr Nephrol. 2012 Jul;27(7):1165-77.

Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy.
Morath C, Beimler J, Opelz G, Scherer S, Schmidt J, Macher-Goeppinger S, Klein K, Sommerer C, Schwenger V, Zeier M, Süsal C.
Transpl Int. 2012 May;25(5):506-17.

Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses.
Ranzinger J, Rustom A, Abel M, Leyh J, Kihm L, Witkowski M, Scheurich P, Zeier M, Schwenger V.
PLoS One. 2011;6(12):e29537.

Recompensation of heart and kidney function after treatment with peritoneal dialysis in a case of congestive heart failure.
Kihm LP, Hankel V, Zugck C, Remppis A, Schwenger V.
Case Rep Med. 2011;2011:197816.

Prognostic value of standard parameters as predictors for long-term renal replacement therapy after liver transplantation.
Weigand K, Bauer E, Encke J, Schmidt J, Stremmel W, Schwenger V.
Nephron Clin Pract. 2011;119(4):c342-7.

Cloudy dialysate-reconsidering initial empiric therapy.
Normann J, Schwenger V.
NDT Plus. 2011 Dec;4(6):437-8.

Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.
Madhusudhan T, Wang H, Straub BK, Gröne E, Zhou Q, Shahzad K, Müller-Krebs S, Schwenger V, Gerlitz B, Grinnell BW, Griffin JH, Reiser J, Gröne HJ, Esmon CT, Nawroth PP, Isermann B.
Blood. 2012 Jan 19;119(3):874-83.

[Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment].
Mahfoud F, Vonend O, Bruck H, Clasen W, Eckert S, Frye B, Haller H, Hausberg M, Hoppe UC, Hoyer J, Hahn K, Keller T, Krämer BK, Kreutz R, Potthoff SA, Reinecke H, Schmieder R, Schwenger V, Kintscher U, Böhm M, Rump LC; Arbeitsgemeinschaft Herz und Niere der Deutschen Gesellschaftfür Kardiologie – Herz- und Kreislaufforschunge V und der Deutschen Gesellschaft für Nephrologiee  V sowie der Deutschen Hochdruckliga e V DHL® – DeutscheGesellschaft für Hypertonie und Prävention.
Dtsch Med Wochenschr. 2011 Nov;136(47):2418.

[Erythropoiesis stimulating agents].
Hoffmann M, Schwenger V.
Ther Umsch. 2011 Nov;68(11):650-4.

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J.
Nat Med. 2011 Jul 31;17(8):952-60.

Henoch-Schönlein purpura in adults is not uncommon in elderly patients with an adverse prognosis.
Schaier M, Freitag J, Dikow R, Sommerer C, Gross-Weissmann ML, Waldherr R, Andrassy K, Zeier M, Schwenger V.
Clin Nephrol. 2011 Jul;76(1):49-56.

Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.
Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, Adaikalakoteswari A, Thornalley PJ, Hammes HP, Nawroth PP, Zeier M, Schwenger V.
J Am Soc Nephrol. 2011 May;22(5):914-26.

The role of pretransplant dialysis modality on renal allograft outcome.
Schwenger V, Döhler B, Morath C, Zeier M, Opelz G.
Nephrol Dial Transplant. 2011 Nov;26(11):3761-6.

Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.
Wang H, Madhusudhan T, He T, Hummel B, Schmidt S, Vinnikov IA, Shahzad K, Kashif M, Muller-Krebs S, Schwenger V, Bierhaus A, Rudofsky G, Nawroth PP, Isermann B.
Blood. 2011 May 12;117(19):5231-42.

Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.
Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, Schnitzler P, Sommerer C.
Am J Kidney Dis. 2011 May;57(5):716-23.

Hepatic and renal failure after anterior myocardial infarction induced apical ventricular septal defect.
Lossnitzer D, Schwenger V, Lehrke S, Giannitsis E, Zeier M, Katus HA, Steen H.
Case Rep Med. 2010;2010:645236.

HLA-DRB1*0102 is associated with TINU syndrome and bilateral, sudden-onset anterior uveitis but not with interstitial nephritis alone.
Mackensen F, David F, Schwenger V, Smith LK, Rajalingam R, Levinson RD, Austin CR, Houghton D, Martin TM, Rosenbaum JT.
Br J Ophthalmol. 2011 Jul;95(7):971-5.

An integrative approach for the transplantation of high-risk sensitized patients.
Morath C, Beimler J, Opelz G, Ovens J, Scherer S, Schmidt J, Schmied B, Gross ML, Schwenger V, Zeier M, Süsal C.
Transplantation. 2010 Sep 27;90(6):645-53.

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.
Schaier M, Scholl C, Scharpf D, Hug F, Bönisch-Schmidt S, Dikow R, Schmitt WH, Schwenger V, Zeier M, Sommerer C.
Rheumatology (Oxford). 2010 Nov;49(11):2061-7.

Uremia aggravates left ventricular remodeling after myocardial infarction.
Dikow R, Schmidt U, Kihm LP, Schaier M, Schwenger V, Gross ML, Katus HA, Zeier M, Hardt SE.
Am J Nephrol. 2010;32(1):13-22.

Immunoadsorption in nephrology and kidney transplantation.
Schwenger V, Morath C.
Nephrol Dial Transplant. 2010 Aug;25(8):2407-13.

Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
Sommerer C, Müller-Krebs S, Schaier M, Glander P, Budde K, Schwenger V, Mikus G, Zeier M.
Br J Clin Pharmacol. 2010 Apr;69(4):346-57.

Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft.
Morath C, Zeier M, Döhler B, Schmidt J, Nawroth PP, Schwenger V, Opelz G.
Clin J Am Soc Nephrol. 2010 Mar;5(3):549-52.

Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure.
Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Wieslander A, Haug U, Zeier M, Schwenger V.
Perit Dial Int. 2010 Jan-Feb;30(1):35-40.

Pharmacokinetics of linezolid in septic patients with and without extended dialysis.
Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA.
Eur J Clin Pharmacol. 2010 Mar;66(3):291-8.

Simultaneous pancreas-kidney transplantation in type 1 diabetes.
Morath C, Schmied B, Mehrabi A, Weitz J, Schmidt J, Werner J, Buchler MW, Morcos M, Nawroth PP, Schwenger V, Doehler B, Opelz G, Zeier M.
Clin Transplant. 2009 Dec;23 Suppl 21:115-20.

Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.
Morath C, Schmied B, Mehrabi A, Weitz J, Schmidt J, Werner J, Buchler MW, Morcos M, Nawroth PP, Schwenger V, Doehler B, Opelz G, Zeier M.
Clin Transplant. 2009 Dec;23 Suppl 21:33-6.

Optimal blood pressure control versus additional immunosuppressive therapy in idiopathic membranous nephropathy - a retrospective analysis.
Dikow R, Quentmeier P, Schwenger V, Waldherr R, Andrassy K, Ritz E, Zeier M.
Clin Nephrol. 2009 Nov;72(5):366-72.

C. elegans as model for the study of high glucose- mediated life span reduction.
Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, Oikonomou D, Ibrahim Y, Pfisterer F, Rabbani N, Thornalley P, Sayed A, Fleming T, Humpert P, Schwenger V, Zeier M, Hamann A, Stern D, Brownlee M, Bierhaus A, Nawroth P, Morcos M.
Diabetes. 2009 Nov;58(11):2450-6.

Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus.
Kihm LP, Hinkel UP, Michael K, Sommerer C, Seckinger J, Morath C, Zeier M, Schwenger V.
Transplantation. 2009 Jul 27;88(2):261-5.

Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats.
Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM.
Basic Res Cardiol. 2009 Sep;104(5):571-9.

CAPD: developments during changing times.
Furkert J, Zeier M, Schwenger V.
Perit Dial Int. 2009 Jan-Feb;29(1):115-6. No abstract available.

Acute phase reaction to gadolinium-DTPA in dialysis patients.
Steen H, Giannitsis E, Sommerer C, Bahner U, Brandl M, Merbach C, Merten C, Ritz E, Katus HA, Zeier M, Schwenger V.
Nephrol Dial Transplant. 2009 Apr;24(4):1274-7.

Gastrointestinal hemorrhage in hemodialysis patients.
Furkert JD, Zeier M, Schwenger V.
Z Gastroenterol. 2008 Nov;46(11):1266-9.

Clinical value of automatic reporting of estimated glomerular filtration rate in geriatrics.
Kurtal H, Schwenger V, Azzaro M, Abdollahnia N, Steinhagen-Thiessen E, Nieczaj R, Schulz RJ.
Gerontology. 2009;55(3):288-95.

Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.
Furkert J, Zeier M, Schwenger V.
Perit Dial Int. 2008 Nov-Dec;28(6):637-40.

Dual regulation of renal Kir7.1 potassium channels by protein Kinase A and protein Kinase C.
Zhang W, Zitron E, Bloehs R, Müller-Krebs S, Scholz E, Zeier M, Katus H, Karle C, Schwenger V.
Biochem Biophys Res Commun. 2008 Dec 19;377(3):981-6.

Continuous ambulatory peritoneal dialysis--developments during changing times.
Furkert JD, Zeier M, Schwenger V.
Nephron Clin Pract. 2008;110(2):c139-43.

Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
J Hypertens. 2008 Nov;26(11):2213-9.

Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized rats.
Morath C, Ratzlaff K, Dechow C, Schwenger V, Schaier M, Zeier B, Peters J, Tsukada M, Zouboulis CC, Waldherr R, Gross ML, Ritz E, Zeier M, Wagner J.
J Mol Med (Berl). 2009 Jan;87(1):53-64.

Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo.
Morath C, Reuter H, Simon V, Krautkramer E, Muranyi W, Schwenger V, Goulimari P, Grosse R, Hahn M, Lichter P, Zeier M.
Am J Transplant. 2008 Sep;8(9):1786-97.

Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
Morcos M, Schlotterer A, Sayed AA, Kukudov G, Oikomonou D, Ibrahim Y, Pfisterer F, Schneider J, Bozorgmehr F, Rudofsky G Jr, Schwenger V, Kientsch-Engels R, Hamann A, Zeier M, Dugi K, Yard B, Humpert PM, van der Woude F, Nawroth PP, Bierhaus A.
Horm Metab Res. 2008 Nov;40(11):752-9.

[Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection].
Marx J, Schwenger V, Blank N, Stremmel W, Encke J.
Internist (Berl). 2008 Sep;49(9):1120-5.

RAGE expression in the human peritoneal membrane.
Kihm LP, Wibisono D, Müller-Krebs S, Pfisterer F, Morath C, Gross ML, Morcos M, Seregin Y, Bierhaus A, Nawroth PP, Zeier M, Schwenger V.
Nephrol Dial Transplant. 2008 Oct;23(10):3302-6.

Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure.
Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Deppisch R, Wieslander A, Henle T, Penndorf I, Oh J, Reiser J, Nawroth PP, Zeier M, Schwenger V.
Eur J Clin Invest. 2008 May;38(5):296-305.

The patient with C-ANCA/PR3-ANCA-positive crescentic pauci-immune glomerulonephritis and recurrence of nephritic sediment.
Andrassy M, Sis J, Waldherr R, Zeier M, Schwenger V.
Nephrol Dial Transplant. 2008 Jun;23(6):2084-7

Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans.
Morcos M, Du X, Pfisterer F, Hutter H, Sayed AA, Thornalley P, Ahmed N, Baynes J, Thorpe S, Kukudov G, Schlotterer A, Bozorgmehr F, El Baki RA, Stern D, Moehrlen F, Ibrahim Y, Oikonomou D, Hamann A, Becker C, Zeier M, Schwenger V, Miftari N, Humpert P, Hammes HP, Buechler M, Bierhaus A, Brownlee M, Nawroth PP.
Aging Cell. 2008 Mar;7(2):260-9.

Autosomal dominant polycystic kidney disease.
Schwenger V, Zeier M.
Saudi J Kidney Dis Transpl. 1999 Jan-Mar;10(1):7-20. No abstract available.

Cardiac biomarkers are influenced by dialysis characteristics.
Sommerer C, Heckele S, Schwenger V, Katus HA, Giannitsis E, Zeier M.
Clin Nephrol. 2007 Dec;68(6):392-400.

Sirolimus in renal transplantation.
Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii61-viii65. Review.

Use of erythropoietin after solid organ transplantation.
Schwenger V, Morath C, Zeier M.
Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii47-viii49. Review.

Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function.
Morath C, Miftari N, Dikow R, Hainer C, Zeier M, Morgera S, Weigand MA, Schwenger V.
Nephrol Dial Transplant. 2008 Jan;23(1):421-2.

Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T.
Sommerer C, Giannitsis E, Schwenger V, Zeier M.
Nephron Clin Pract. 2007;107(3):c77-81.

Good MRI images: to Gad or not to Gad?
Steen H, Schwenger V.
Pediatr Nephrol. 2007 Sep;22(9):1239-42.

Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading.
Morath C, Sis J, Haensch GM, Zeier M, Andrassy K, Schwenger V.
Nephrol Dial Transplant. 2007 Sep;22(9):2701-4.

Aquaporin-1 channel function is positively regulated by protein kinase C.
Zhang W, Zitron E, Hömme M, Kihm L, Morath C, Scherer D, Hegge S, Thomas D, Schmitt CP, Zeier M, Katus H, Karle C, Schwenger V.
J Biol Chem. 2007 Jul 20;282(29):20933-40.

Long-term treatment of central Cushing's syndrome with rosiglitazone.
Morcos M, Fohr B, Tafel J, Pfisterer F, Hamann A, Humpert P, Bode H, Schwenger V, Zeier M, Becker C, Kasperk C, Schilling T, Hammes HP, Bierhaus A, Nawroth PP.
Exp Clin Endocrinol Diabetes. 2007 May;115(5):292-7.

[Diabetic nephropathy].
Morcos M, Zeier M, Schwenger V.
Dtsch Med Wochenschr. 2007 May 11;132(19):1039-42.

Cardiac biomarkers and survival in haemodialysis patients.
Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M.
Eur J Clin Invest. 2007 May;37(5):350-6.

The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists.
Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V.
Neurology. 2007 May 15;68(20):1742-4.

Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.
Morath C, Schwenger V, Ksoll-Rudek D, Sommerer C, Beimler J, Schmidt J, Zeier M.
Transplant Proc. 2007 Jan-Feb;39(1):99-102.

Real-time contrast-enhanced sonography in renal transplant recipients.
Schwenger V, Hinkel UP, Nahm AM, Morath C, Zeier M.
Clin Transplant. 2006;20 Suppl 17:51-4.

Antifibrotic actions of mycophenolic acid.
Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W.
Clin Transplant. 2006;20 Suppl 17:25-9.

Color Doppler indices of renal allografts depend on vascular stiffness of the transplant recipients.
Schwenger V, Keller T, Hofmann N, Hoffmann O, Sommerer C, Nahm AM, Morath C, Zeier M, Krumme B.
Am J Transplant. 2006 Nov;6(11):2721-4.

[Renal replacement therapy in the intensive care unit].
Morath C, Miftari N, Dikow R, Hainer C, Zeier M, Schwenger V, Weigand MA.
Anaesthesist. 2006 Aug;55(8):901-13; quiz 914

Contrast-enhanced sonography as early diagnostic tool of chronic allograft nephropathy.
Schwenger V, Zeier M.
Nephrol Dial Transplant. 2006 Oct;21(10):2694-6.

Color doppler ultrasonography in the diagnostic evaluation of renal allografts.
Schwenger V, Hinkel UP, Nahm AM, Morath C, Zeier M.
Nephron Clin Pract. 2006;104(3):c107-12.

GDP and AGE receptors: mechanisms of peritoneal damage.
Schwenger V.
Contrib Nephrol. 2006;150:77-83.

Lymphoid interstitial lung disease in a patient with acute tubulointerstitial nephritis and uveitis: a new facet of a rare syndrome?
Hofmann N, Müller KM, Morath C, Waldherr R, Zeier M, Schwenger V.
Am J Kidney Dis. 2006 Apr;47(4):e55-9.

Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy.
Schwenger V, Korosoglou G, Hinkel UP, Morath C, Hansen A, Sommerer C, Dikow R, Hardt S, Schmidt J, Kücherer H, Katus HA, Zeier M.
Am J Transplant. 2006 Mar;6(3):609-15.

A nephrotic patient with tumour necrosis factor receptor-associated periodic syndrome, IgA nephropathy and CNS involvement.
Rudofsky G Jr, Hoffmann F, Müller K, Filser M, Lohse P, Beimler J, Schwenger V.
Nephrol Dial Transplant. 2006 Apr;21(4):1109-12.

Pulmonary cavernae in Wegener's granulomatosis.
Schwenger V, Morath C, Kihm LP, Andrassy K, Zeier M.
Nephrol Dial Transplant. 2006 Mar;21(3):818.

Late referral--a major cause of poor outcome in the very elderly dialysis patient.
Schwenger V, Morath C, Hofmann A, Hoffmann O, Zeier M, Ritz E.
Nephrol Dial Transplant. 2006 Apr;21(4):962-7.

[Dialysis in Germany: new medications and new technical possibilities. Interview by Sonja Böhm].
Schwenger V.
Dtsch Med Wochenschr. 2005 Oct 28;Suppl 1:54.

Salt--a potential 'uremic toxin'?
Ritz E, Dikow R, Morath C, Schwenger V.
Blood Purif. 2006;24(1):63-6.

Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M.
J Am Soc Nephrol. 2006 Jan;17(1):199-207.

Transmission of malignancy with solid organ transplants.
Morath C, Schwenger V, Schmidt J, Zeier M.
Transplantation. 2005 Sep 27;80(1 Suppl):S164-6.

An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients.
Schwenger V, Morath C, Schönfelder K, Klein W, Weigel K, Deppisch R, Henle T, Ritz E, Zeier M.
Nephrol Dial Transplant. 2006 Feb;21(2):383-8.

Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft.
Morath C, Rohmeiss P, Schwenger V, Waldherr R, Ritz E, Zeier M, Fallsehr C, Kloor M, von Knebel Doeberitz M, Andrassy J, Huckenbeck W, Büchler M, Opelz G.
Transplantation. 2005 Aug 27;80(4):540-2.

Lifestyle modification and progressive renal failure.
Ritz E, Schwenger V.
Nephrology (Carlton). 2005 Aug;10(4):387-92.

Hemodialysis--from early days to tomorrow.
Ritz E, Dikow R, Schwenger V, Gross ML.
Contrib Nephrol. 2005;149:1-9.

[Integrated skills laboratory concept for undergraduate training in internal medicine].
Nikendei C, Schilling T, Nawroth P, Hensel M, Ho AD, Schwenger V, Zeier M, Herzog W, Schellberg D, Katus HA, Dengler T, Stremmel W, Müller M, Jünger J.
Dtsch Med Wochenschr. 2005 May 6;130(18):1133-8. German.

Is the sauna a common place for experiencing acute renal failure?
Hofmann N, Waldherr R, Schwenger V.
Nephrol Dial Transplant. 2005 Jan;20(1):235-7.

[10 minute consultation: hypokalemia as incidental finding].
Morath C, Ritz E, Schwenger V.
MMW Fortschr Med. 2004 Sep 23;146(39):67-8.

Malignancy in renal transplantation.
Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M.
J Am Soc Nephrol. 2004 Jun;15(6):1582-8.

How can the poor outcomes for diabetic dialysis patients be improved?
Schwenger V, Zeier M, Ritz E.
Semin Dial. 2004 May-Jun;17(3):186-7.

[Uremic patients--late referral, early death].
Schwenger V, Hofmann A, Khalifeh N, Meyer T, Zeier M, Hörl WH, Ritz E.
Dtsch Med Wochenschr. 2003 May 30;128(22):1216-20.

Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E.
Kidney Int. 2003 Jan;63(1):298-305.

Activation of tubular epithelial cells in diabetic nephropathy.
Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, Tritschler H, Kasper M, Schwenger V, Hamann A, Dugi KA, Schmidt AM, Stern D, Ziegler R, Haering HU, Andrassy M, van der Woude F, Nawroth PP.
Diabetes. 2002 Dec;51(12):3532-44.

Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report.
Schwenger V, Mündlein E, Dagrosa EE, Fahr AM, Zeier M, Mikus G, Andrassy K.
Infection. 2002 Oct;30(5):257-61.

Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversible.
Sommerer C, Hergesell O, Nahm AM, Schwenger V, Waldherr R, Andrassy K, Zeier M.
Nephron. 2002 Oct;92(2):339-45.

Hypertension after renal transplantation.
Schwenger V, Zeier M, Ritz E.
Ann Transplant. 2001;6(4):25-30.

[Palpable resistance in the right renal area. Xanthogranulomatous pyelonephritis with fistulization in the colon ascendens and M. psoas major].
Weber MA, Wasser K, Schwenger V, Hallscheidt P, Nahm AM, Delorme S.
Radiologe. 2002 Jan;42(1):46-50.

Do AV fistulas contribute to cardiac mortality in hemodialysis patients?
Dikow R, Schwenger V, Zeier M, Ritz E.
Semin Dial. 2002 Jan-Feb;15(1):14-7.

Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
Rengelshausen J, Hull WE, Schwenger V, Göggelmann C, Walter-Sack I, Bommer J.
Am J Kidney Dis. 2002 Feb;39(2):E10.

How should we manage anaemia in patients with diabetes?
Dikow R, Schwenger V, Schömig M, Ritz E.
Nephrol Dial Transplant. 2002;17 Suppl 1:67-72.

Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure.
Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Schwenger V, von Eckardstein A.
J Am Soc Nephrol. 2002 Feb;13(2):461-9.

[Incidence and clinical characteristics of renal insufficiency in diabetic patients].
Schwenger V, Müssig C, Hergesell O, Zeier M, Ritz E.
Dtsch Med Wochenschr. 2001 Nov 23;126(47):1322-6.

Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate.
Bostom AG, Kronenberg F, Jacques PF, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Schwenger V, Riegler P, Selhub J.
Atherosclerosis. 2001 Nov;159(1):219-23.

Hypertension after renal transplantation.
Schwenger V, Zeier M, Ritz E.
Curr Hypertens Rep. 2001 Oct;3(5):434-9.

Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise?
Ritz E, Schwenger V, Zeier M, Rychlik I.
Nephrol Dial Transplant. 2001 Aug;16(8):1550-4.

Advanced glycation endproducts (AGEs) as uremic toxins.
Schwenger V, Zeier M, Henle T, Ritz E.
Nahrung. 2001 Jun;45(3):172-6.

Chronic renal transplantation: a model for the hyperhomocysteinemia of renal insufficiency.
Bostom AG, Kronenberg F, Gohh RY, Schwenger V, Kuen E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Ritz E, Selhub J.
Atherosclerosis. 2001 May;156(1):227-30.

[Antihypertensive therapy in diabetic patients. Almost as important as controlling blood glucose].
Ritz E, Zeier M, Schwenger V.
MMW Fortschr Med. 2000 Nov 23;142(47):34-8.

Atherosclerotic complications after renal transplantation.
Ritz E, Schwenger V, Wiesel M, Zeier M.
Transpl Int. 2000;13 Suppl 1:S14-9.

Circadian rhythm of blood pressure in renal disease.
Schömig M, Schwenger V, Ritz E.
Curr Hypertens Rep. 2000 Oct;2(5):490-4.

The optimal target hemoglobin.
Ritz E, Schwenger V.
Semin Nephrol. 2000 Jul;20(4):382-6.

Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.
Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A.
J Am Soc Nephrol. 2000 Jan;11(1):105-15.

Antihypertensive therapy in renal patients - benefits and difficulties.
Schwenger V, Zeier M, Ritz E.
Nephron. 1999;83(3):202-13.

How can we improve prognosis in diabetic patients with end-stage renal disease?
Ritz E, Koch M, Fliser D, Schwenger V.
Diabetes Care. 1999 Mar;22 Suppl 2:B80-3.

Audit of antihypertensive treatment in patients with renal failure.
Schwenger V, Ritz E.
Nephrol Dial Transplant. 1998 Dec;13(12):3091-5.

CRP levels in autoimmune disease can be specified by measurement of procalcitonin.
Schwenger V, Sis J, Breitbart A, Andrassy K.
Infection. 1998 Sep-Oct;26(5):274-6.

Dr. Markus Krautter

PD Dr. Jörg Latus

Dr. Daniel Kitterer